Between 1 and 10 September 2026, 45,000 Series 19 stock acquisition rights were exercised and 4,500,000 new shares were delivered. As a result, the number of unexercised stock acquisition rights decreased from 138,700 to 93,700.
Exercise of stock acquisition rights with an exercise price adjustment clause issued through a third-party allotment
4,500,000 new shares (0 treasury shares transferred)
The lower thin line represents the existing number of shares to which these shares will be added.
4.2% (4,500,000 new shares delivered from the beginning of the month ÷ 106,464,098 shares outstanding at the end of the previous month. No dilution rate was stated in the filing.)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise of stock acquisition rights with an exercise price adjustment clause issued through a third-party allotment |
| Number of shares to be issued or disposed of | 4,500,000 new shares (0 treasury shares transferred) |
| Intended allottee | EVO FUND (allottee of the Series 19 stock acquisition rights) |
| Dilution Rate | 4.2% (4,500,000 new shares delivered from the beginning of the month ÷ 106,464,098 shares outstanding at the end of the previous month. No dilution rate was stated in the filing.) |
| Total number of issued shares | 106,464,098 shares (at the end of the month preceding the subject month) → 110,964,098 shares (if the shares delivered from the beginning of the month are added to the shares outstanding at the end of the previous month) |
| Exercise price | The exercise price from 1 to 10 September was ¥34.0, ¥35.0 or ¥36.0. Details of the exercise price adjustment clause and the adjustment floor: Not disclosed |
| Number of Stock Acquisition Rights | 240,000 stock acquisition rights issued in total. 138,700 unexercised at the end of the previous month; 93,700 unexercised currently |
| Most recent equity financing | Timing 12 June 2026 / Type Series 19 stock acquisition rights with an exercise price adjustment clause issued through a third-party allotment and Series 2 unsecured corporate bonds (private placement) / Amount Not disclosed |
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
To report the large-scale exercise of these stock acquisition rights.